Shun-Ichiro Ogura Selected Research

Photosensitizing Agents (Photosensitizers)

3/2023	Polymeric iron chelators for enhancing 5-aminolevulinic acid-induced photodynamic therapy.
2/2022	Current status of photodynamic technology for urothelial cancer.
1/2022	4'-Nitrobiphenyl thioglucoside as the Smallest, fluorescent photosensitizer with cancer targeting ligand.
9/2021	Sunitinib with photoirradiation-mediated reactive oxygen species generation induces apoptosis of renal cell carcinoma cells.
6/2019	A Twist-Assisted Biphenyl Photosensitizer Passable Through Glucose Channel.
1/2017	Coating lanthanide nanoparticles with carbohydrate ligands elicits affinity for HeLa and RAW264.7 cells, enhancing their photodamaging effect.
9/2015	The Effect of Coatings on the Affinity of Lanthanide Nanoparticles to MKN45 and HeLa Cancer Cells and Improvement in Photodynamic Therapy Efficiency.
1/2012	Improvement of tumor localization of photosensitizers for photodynamic therapy and its application for tumor diagnosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shun-Ichiro Ogura Research Topics

Disease

38	Neoplasms (Cancer) 09/2023 - 04/2006
6	Urinary Bladder Neoplasms (Bladder Cancer) 06/2023 - 09/2013
5	Stomach Neoplasms (Stomach Cancer) 09/2023 - 09/2012
5	Glioma (Gliomas) 03/2022 - 06/2012
4	Carcinoma (Carcinomatosis) 12/2014 - 12/2008
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/2012 - 12/2008
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2012 - 04/2007
2	Brain Neoplasms (Brain Tumor) 11/2011 - 09/2011
1	Phototoxic Dermatitis (Phototoxicity) 09/2023
1	COVID-19 01/2023
1	Hypotension (Low Blood Pressure) 03/2022
1	Urologic Neoplasms (Urological Cancer) 02/2022
1	Renal Cell Carcinoma (Grawitz Tumor) 09/2021
1	Prostatic Neoplasms (Prostate Cancer) 09/2021
1	Kidney Neoplasms (Kidney Cancer) 09/2021
1	Neoplasm Metastasis (Metastasis) 03/2017
1	Hypoxia (Hypoxemia) 01/2015
1	Peritoneal Neoplasms 12/2014
1	Ovarian Neoplasms (Ovarian Cancer) 12/2014
1	Malaria 12/2013

Drug/Important Bio-Agent (IBA)

26	protoporphyrin IXIBA 09/2023 - 04/2006
26	AcidsIBA 03/2023 - 09/2011
16	1-phenyl-3,3-dimethyltriazene (PDT)IBA 09/2023 - 01/2012
8	Aminolevulinic Acid (Levulan)FDA Link 09/2023 - 02/2014
8	Photosensitizing Agents (Photosensitizers)IBA 03/2023 - 01/2012
7	PorphyrinsIBA 06/2023 - 09/2011
4	Heme (Haem)IBA 03/2023 - 12/2013
4	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2022 - 02/2013
3	Tumor Biomarkers (Tumor Markers)IBA 02/2022 - 12/2008
3	LigandsIBA 01/2022 - 01/2017
3	ATP-Binding Cassette Transporters (ABC Transporters)IBA 07/2015 - 09/2011
3	Adenosine Triphosphate (ATP)IBA 03/2014 - 09/2011
2	IronIBA 03/2023 - 01/2017
2	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 06/2019
2	Lanthanoid Series Elements (Lanthanides)IBA 01/2017 - 09/2015
2	ProdrugsIBA 01/2015 - 06/2012
2	Proteins (Proteins, Gene)FDA Link 03/2014 - 12/2008
2	Messenger RNA (mRNA)IBA 09/2013 - 11/2011
2	Conditioned Culture MediaIBA 10/2012 - 12/2008
2	proneurotensinIBA 10/2012 - 12/2008
1	mangostinIBA 09/2023
1	Chelating AgentsIBA 03/2023
1	Amino Acids FDA Link 03/2023
1	Angiotensin-Converting Enzyme 2IBA 01/2023
1	ferrous citrate FDA Link 12/2022
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2022
1	diphenyl (biphenyl)IBA 01/2022
1	Member 2 Subfamily G ATP Binding Cassette TransporterIBA 09/2021
1	Therapeutic UsesIBA 09/2021
1	Sunitinib (Sutent)FDA Link 09/2021
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 09/2020
1	Schiff Bases (Schiff Base)IBA 12/2017
1	Contrast MediaIBA 03/2017
1	GadoliniumIBA 03/2017
1	Indicators and Reagents (Reagents)IBA 01/2017
1	MonosaccharidesIBA 01/2017
1	CarbohydratesIBA 01/2017
1	Growth InhibitorsIBA 11/2016
1	CyclinsIBA 01/2015
1	Oxygen (Dioxygen)IBA 01/2015
1	EnzymesIBA 01/2015
1	Adenosine Triphosphatases (ATPase)IBA 01/2015
1	PC 16IBA 12/2014
1	NeurotensinIBA 10/2012
1	AntibodiesIBA 10/2012
1	neuromedin NIBA 10/2012
1	Peptides (Polypeptides)IBA 09/2012
1	Radiation-Sensitizing AgentsIBA 06/2012
1	MetalloporphyrinsIBA 01/2012
1	Coproporphyrinogen Oxidase (Coproporphyrinogen III Oxidases)IBA 11/2011
1	Protein Kinase InhibitorsIBA 09/2011
1	ErbB Receptors (EGF Receptor)IBA 04/2007
1	HematoporphyrinsIBA 04/2006
1	Singlet OxygenIBA 04/2006

Therapy/Procedure

18	Photochemotherapy (Photodynamic Therapy) 09/2023 - 01/2012
10	Therapeutics 03/2023 - 04/2006
3	Drug Therapy (Chemotherapy) 01/2023 - 02/2014
1	Radiotherapy 01/2023
1	Controlled Hypotension 03/2022
1	Cytoreduction Surgical Procedures 12/2014
1	Hyperthermic Intraperitoneal Chemotherapy 12/2014
1	Oral Administration 02/2014
1	Aftercare (After-Treatment) 02/2013